Nutritional Status in Advanced Parkinson’s Disease: Preliminary Results.
Objective: To analyze the relationship between nutritional intake and weight aspects in 3 groups of patients with Parkinson's disease (PD) who are receiving different pharmacological…Use of a wearable medical device for LCIG tube adjustment: a user case
Objective: To identify objectively the change in motor symptoms in a patient with Parkinson’s Disease (PD) on levodopa-carbidopa intestinal gel (LCIG) treatment with and without…Dopamine agonist utilization prior to the initiation of device aided therapy: data from 150 patients with advanced Parkinson’s disease treated with Levodopa Carbidopa Intestinal Gel
Objective: Objective: To evaluate the usage of dopamine agonists (DA) as part of the last conventional dopaminergic treatment in a large cohort of consecutive patients…Impact of foslevodopa/foscarbidopa on key clinical and patient-reported outcomes in patients with aPD: Responder analysis of two Phase 3 clinical trials
Objective: To evaluate the effect of foslevodopa/foscarbidopa (LDP/CDP, ABBV-951) on clinical and patient-reported outcomes in advanced Parkinson’s disease (aPD) patients using minimal clinically important difference…Effect of freezing of gait and antiparkinsonian medication on joint kinematics and kinetics in gait in patients with Parkinson’s disease
Objective: This study aims to evaluate the interaction between FoG and antiparkinsonian medication on individuals with PD's kinematic and kinetic gait parameters. Background: Regarding Parkinson's…DIFFERENT PATTERNS OF ACUTE SACCADIC RESPONSES TO LEVODOPA CHALLENGE TEST IN DE NOVO PARKINSON’S DISEASE: POSSIBILE PROGNOSTIC IMPLICATIONS
Objective: To explore possible different patterns of acute saccadic responses to Levodopa Challenge Test (LCT) in a de novo drug-naïve Parkinson’s Disease (PD) population and…LFP beta frequency OFF-ON shift in subthalamic nucleus in Parkinson’s disease
Objective: The aim of the current study is to investigate the frequency characteristics of beta activity in Parkinson’s disease. We hypothesized that beta peak central…Subcutaneous Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson’s Disease: Results From a Randomized, Double-blind, Double-dummy Phase 3 Trial
Objective: To evaluate the efficacy and safety/tolerability of 24-hour/day continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa (a soluble formulation of levodopa/carbidopa prodrugs) vs oral levodopa/carbidopa in…Acute polyneuropathy in patients with Parkinson’s disease treated with LCIG
Objective: The aim of the study was to determine whether the daily dose of levodopa equivalent daily dose (LEDD) before and after starting levodopa/carbidopa intestinal…Reported Clinical and Quality-of-Life Outcomes With 24-Hour Levodopa-Carbidopa Intestinal Gel Administration Compared With 16-Hour Administration
Objective: To evaluate any existing differences between the reported outcomes in patients with advanced Parkinson’s disease (APD) using continuous 16-hour (hr) infusions of levodopa-carbidopa intestinal…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 57
- Next Page »